Synopsys Stock Falls on China Ban, But Long-Term Outlook Holds

Synopsys shares declined after the Trump administration restricted EDA software sales to China, representing a 10% revenue loss from the last quarter, leading the company to suspend its fiscal Q3 and full-year 2025 guidance. Despite beating sales and EPS estimates, the China restriction and pending regulatory approval from Chinese regulators for its $35 billion ANSYS acquisition create near-term uncertainty. While analysts maintain a moderate buy rating with an average price target of $607.14, the company's long-term prospects are supported by the eventual ANSYS deal completion and secular trends in advanced chip development.

Analysis

Synopsys (SNPS), a critical Electronic Design Automation (EDA) software provider for the semiconductor industry, is currently navigating significant near-term headwinds despite demonstrating strong underlying fundamentals. The company's shares experienced a sharp decline, nearly 10% on May 28, following the U.S. administration's directive to halt EDA sales to China. This market accounted for approximately 10% of Synopsys's revenue in the last reported quarter, and the restriction led the company to suspend its fiscal Q3 and full-year 2025 guidance. This geopolitical challenge overshadowed robust quarterly financial results, where sales grew 10% and adjusted earnings per share (EPS) rose 22% year-over-year, beating estimates. While China's revenue contribution had already moderated from 15% in the prior fiscal Q2 2024, making it the smallest reported geography, the sales ban introduces considerable uncertainty. This situation is compounded by the pending $35 billion acquisition of ANSYS (ANSS), which still requires regulatory approval from China, anticipated in the first half of 2025; new trade restrictions could influence this approval process. As of June 13, 2025, Synopsys stock was priced at $478.86, with a P/E ratio of 32.98, and had declined approximately 13% over the past 52 weeks (based on the June 11 close). Despite these challenges, Wall Street analysts maintain a "Moderate Buy" consensus rating with an average 12-month price target of $607.14, reflecting an anticipated upside. This cautious optimism is underpinned by long-term secular growth trends in advanced chip development and the strategic importance of the ANSYS acquisition, should it secure approval.

Key Decisions for Investors

• Investors should closely monitor developments in U.S.-China trade policy, particularly regarding EDA sales restrictions, and track the progress of Chinese regulatory approval for the strategically important ANSYS acquisition.
• Given the suspension of financial guidance and heightened geopolitical risks impacting China revenue (previously 10% of total), a cautious stance is warranted in the near term, despite the company's recent strong earnings performance and a P/E ratio of 32.98.
• Long-term focused investors might evaluate the current valuation against the average analyst price target of $607.14 and the company's exposure to secular growth in semiconductor design, while factoring in significant near-term uncertainties tied to the ANSYS deal closure and China market access.